Literature DB >> 184806

Anxiety and sleep after fosazepam.

S Allen, I Oswald.   

Abstract

1 Six volunteers of mean age 59 years received placebo for week, then fosazepam (60 mg) nightly for 3 weeks, then placebo for 3 weeks. Subjective ratings and all-night electrophysiological recordings were made. 2 Fosazepam administration improved subjective sleep quality nut impaired feelings of morning vitality. Its withdrawal was associated with anxiety, impaired concentration and continuing impairment of morning vitality. Measured sleep duration increased on fosazepam, sleep was less broken, slow wave sleep stages 3 and 4 diminished in duration and so did REM sleep. 3 Despite the short-life of fosazepam some drug effects persisted for several days after withdrawal, suggesting action of a long half-life metabolite.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 184806      PMCID: PMC1428810          DOI: 10.1111/j.1365-2125.1976.tb00584.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Five Weeks to Escape the Sleeping-pill Habit.

Authors:  I Oswald; R G Priest
Journal:  Br Med J       Date:  1965-11-06

2.  Flunitrazepam (Ro 5-4200) and sleep cycle in insomniac patients.

Authors:  J M Monti; H M Trenchi; F Morales; L Monti
Journal:  Psychopharmacologia       Date:  1974-03-09

3.  A psychophysiological study of nightmares and night terrors. The suppression of stage 4 night terrors with diazepam.

Authors:  C Fisher; E Kahn; A Edwards; D M Davis
Journal:  Arch Gen Psychiatry       Date:  1973-02

4.  Effects of placebo and flurazepam on sleep patterns in insomniac subjects.

Authors:  J Kales; A Kales; E O Bixler; E S Slye
Journal:  Clin Pharmacol Ther       Date:  1971 Jul-Aug       Impact factor: 6.875

5.  Hypnotic drugs and their effectiveness. All-night EEG studies of insomniac subjects.

Authors:  A Kales; C Allen; M B Scharf; J D Kales
Journal:  Arch Gen Psychiatry       Date:  1970-09

6.  Hypnotics and altered sleep-dream patterns. II. All-night EEG studies of chloral hydrate, flurazepam, and methaqualone.

Authors:  A Kales; J D Kales; M B Scharf; T L Tan
Journal:  Arch Gen Psychiatry       Date:  1970-09

7.  The effects of long term administration of psychotropic drugs on human sleep. VI. The effects of chlordiazepoxide.

Authors:  E Hartmann; J Cravens
Journal:  Psychopharmacologia       Date:  1973
  7 in total
  15 in total

1.  Viloxazine, sleep, and subjective feelings.

Authors:  V Brezinová; K Adam; K Chapman; I Oswald; J Thomson
Journal:  Psychopharmacology (Berl)       Date:  1977-12-19       Impact factor: 4.530

2.  Evaulation of the effect of fosazepam (a new benzodiazepine), nitrazepam and placebo on sleep patterns in normal subjects.

Authors:  A M Risberg; S Henricsson; D H Ingvar
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

3.  Clazepam: pharmacokinetics and effects on performance.

Authors:  J F Giudicelli; A Berdeaux; N Idrissi; C Richer
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

4.  Withdrawal symptoms and rebound anxiety after six weeks course of diazepam.

Authors:  I Oswald
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15

5.  Anxiety caused by a short-life hypnotic.

Authors:  K Morgan; I Oswald
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-27

6.  Abuse of benzodiazepines.

Authors:  M Peet; L Moonie
Journal:  Br Med J       Date:  1977-03-12

7.  No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study.

Authors:  F Kamali
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Benzodiazepine hypnotics remain effective for 24 weeks.

Authors:  I Oswald; C French; K Adam; J Gilham
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-20

Review 9.  Temazepam: a review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-05       Impact factor: 9.546

10.  Mianserin in the treatment of depressive illness and anxiety states in general practice.

Authors:  J E Murphy
Journal:  Br J Clin Pharmacol       Date:  1978       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.